TGF‐β‐activated kinase‐1 inhibitor LL‐Z1640‐2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF‐α and RANKL expression

OBJECTIVES: Aberrant NLRP3 inflammasome activation has been demonstrated in rheumatoid arthritis (RA), which may contribute to debilitating inflammation and bone destruction. Here, we explored the efficacy of the potent TGF‐β‐activated kinase‐1 (TAK1) inhibitor LL‐Z1640‐2 (LLZ) on joint inflammation...

Descripción completa

Detalles Bibliográficos
Autores principales: Tenshin, Hirofumi, Teramachi, Jumpei, Ashtar, Mohannad, Hiasa, Masahiro, Inoue, Yusuke, Oda, Asuka, Tanimoto, Kotaro, Shimizu, So, Higa, Yoshiki, Harada, Takeshi, Oura, Masahiro, Sogabe, Kimiko, Hara, Tomoyo, Sumitani, Ryohei, Maruhashi, Tomoko, Sebe, Mayu, Tsutsumi, Rie, Sakaue, Hiroshi, Endo, Itsuro, Matsumoto, Toshio, Tanaka, Eiji, Abe, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770968/
https://www.ncbi.nlm.nih.gov/pubmed/35079379
http://dx.doi.org/10.1002/cti2.1371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770968/
https://www.ncbi.nlm.nih.gov/pubmed/35079379
http://dx.doi.org/10.1002/cti2.1371

Ejemplares similares